Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06943586 · ClinicalTrials.gov registry record · NA
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
A NA study of Stroke and Transient Ischemic Attack (TIA), sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT06943586 is a NA study of Stroke and Transient Ischemic Attack (TIA) that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 200 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06943586, a NA study of Stroke and Transient Ischemic Attack (TIA), is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
Conditions Studied
Interventions
- GENETIC CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-04-09 |
| Est. Completion | 2029-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06943586
The ClinicalTrials.gov registry entry for NCT06943586 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (98% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy) is the first listed.
NCT06943586 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT06943586 about?
NCT06943586 is a clinical study titled "Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing". The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
What is the current status of trial NCT06943586?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2025-04-09. Estimated completion is 2029-04-01.
What conditions does trial NCT06943586 study?
This clinical trial studies the following conditions: Stroke, Transient Ischemic Attack (TIA).
What interventions are being tested in trial NCT06943586?
The interventions under investigation include: CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy) (GENETIC).
Who is sponsoring clinical trial NCT06943586?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06943586 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
-
Safety and Feasibility of an ExoNET for Supination Assistance for Stroke Survivors
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.